US83422E2046 - Common Stock
SOLID BIOSCIENCES INC
NASDAQ:SLDB (5/3/2024, 7:18:36 PM)
10.1
-0.13 (-1.27%)
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2018-01-26. SGT-001 and SGT-003 are its gene transfer candidates. Its neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreichs ataxia, and AVB-401 for BAG3 mediated dilated cardiomyopathy. Its SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. In addition to gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows to package multiple transgenes into one vector.
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139
P: 16173374680
CEO: Ilan Ganot
Employees: 87
Website: https://www.solidbio.com/
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired employees.
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...
– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing...
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in...
Solid Biosciences (SLDB) has filed a prospectus for the resale of 19.69M common shares, as indicated in a recent SEC filing.
Here you can normally see the latest stock twits on SLDB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: